Teladoc Gains as Wall Street Reacts to Post-earnings Slump

95
8
Favorite

Teladoc Gains as Wall Street Reacts to Post-earnings Slump

Seeking Alpha2022-02-23

Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（8）

CL777
·2022-02-24
Oversold
Reply
2
Report
DZL
·2022-02-24
Teladoc for 2022
Reply
Like
Report
BlueDaisy
·2022-02-23
Regardless of results, all drop after earnings nowadays.
Reply
3
Report
Wheee
·2022-02-23
Hmm
Reply
2
Report
haoren
·2022-02-23
Nice
Reply
5
Report
Xalier
·2022-02-23
Wa
Reply
4
Report
wyin08
·2022-02-23
Like
Reply
6
Report
飙高音
·2022-02-23
K
Reply
7
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1170972661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-23 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170972661","market":"us","top_or_hot":-1,"title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","media":"Seeking Alpha","content":"<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TDOC","symbol_name":"Teladoc Health Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","article_id":"1170972661","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","pubTimestamp":1645625813,"sourceInfo":null,"weMediaInfo":null,"summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TDOC":"Teladoc Health Inc."},"translate_title":"Teladoc上涨，华尔街对后收益下滑做出反应","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":0.9},"content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9030117514,"gmtCreate":1645662000421,"gmtModify":1676534050165,"author":{"id":"3560241002253187","authorId":"3560241002253187","name":"CL777","avatar":"https://static.tigerbbs.com/e9aef3dd830373a0427a3447b1b564e3","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Oversold&nbsp;","listText":"Oversold&nbsp;","text":"Oversold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030117514","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030360053,"gmtCreate":1645634188595,"gmtModify":1676534047718,"author":{"id":"3582006183410147","authorId":"3582006183410147","name":"DZL","avatar":"https://static.tigerbbs.com/640ac3ae648fded99146300a53c24a5b","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Teladoc for 2022","listText":"Teladoc for 2022","text":"Teladoc for 2022","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030360053","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030389937,"gmtCreate":1645631785717,"gmtModify":1676534047417,"author":{"id":"3582677971530678","authorId":"3582677971530678","name":"BlueDaisy","avatar":"https://static.tigerbbs.com/0747094283743978b62fb8b1ee2cf44c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Regardless of results, all drop after earnings nowadays.&nbsp;","listText":"Regardless of results, all drop after earnings nowadays.&nbsp;","text":"Regardless of results, all drop after earnings nowadays.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030389937","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030397347,"gmtCreate":1645628254909,"gmtModify":1676534046890,"author":{"id":"3580123620847057","authorId":"3580123620847057","name":"Wheee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030397347","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030392038,"gmtCreate":1645627630054,"gmtModify":1676534046848,"author":{"id":"3581803494981906","authorId":"3581803494981906","name":"haoren","avatar":"https://static.tigerbbs.com/959cadb42575ede705b330aa58d68a63","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030392038","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030399929,"gmtCreate":1645626927605,"gmtModify":1676534046538,"author":{"id":"3569445806394527","authorId":"3569445806394527","name":"Xalier","avatar":"https://static.tigerbbs.com/24f0858187f1785be0f6b9d132363a84","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Wa","listText":"Wa","text":"Wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030399929","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030304383,"gmtCreate":1645626384989,"gmtModify":1676534046458,"author":{"id":"3586981337504184","authorId":"3586981337504184","name":"wyin08","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030304383","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9030306708,"gmtCreate":1645625954857,"gmtModify":1676534046411,"author":{"id":"3582709856792743","authorId":"3582709856792743","name":"飙高音","avatar":"https://static.tigerbbs.com/475b76d560816b91289272c06ae8dfff","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030306708","repostId":1170972661,"repostType":4,"repost":{"id":"1170972661","pubTimestamp":1645625813,"share":"https://www.laohu8.com/m/news/1170972661?lang=&edition=full","pubTime":"2022-02-23 22:16","market":"us","language":"en","title":"Teladoc Gains as Wall Street Reacts to Post-earnings Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1170972661","media":"Seeking Alpha","summary":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday fro","content":"<html><head></head><body><p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.</p><p>While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.</p><p>Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,&#34; which could &#34;still achieve full-year projections.”</p><p>Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”</p><p>Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.</p><p>Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.</p><p>“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.</p><p>Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.</p><p>Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”</p><p>“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.</p><p>Meanwhile, Hims &amp; Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Gains as Wall Street Reacts to Post-earnings Slump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Gains as Wall Street Reacts to Post-earnings Slump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials...</p>\n\n<a href=\"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://seekingalpha.com/news/3803635-tdoc-stock-slips-as-analysts-react-to-post-earnings-slump","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170972661","content_text":"Adding ~1% in the pre-market, the shares of Teladoc Health(NYSE:TDOC)have recovered on Wednesday from after-hours losses following the telehealth provider’s Q4 2021 results on Tuesday.While financials for the quarter exceeded the Street forecasts, the guidance for the current quarter fell short of expectations. However, Teladoc (TDOC) set its 2022 outlook ahead of the consensus.Commenting on the results, Barclays analysts led by Steve Valiquette note that the lower-than-expected guidance for Q1 2022 implies “a back-end loaded steep ramp in 2H22,\" which could \"still achieve full-year projections.”Citing the after-hours decline in company shares, Valiquette and the team argue: “Our sense is that some investors may see some risk related to the quarterly cadence that requires the steep ramp in 2H.”Reiterating the Equal Weight rating on the stock, Barclays has cut the EV/Sales multiple to reflect a greater risk. As a result, the new price target at $77, down from $95, implies a premium of ~18% to the last close.Meanwhile, Jefferies analyst Glen Santangelo, with a Hold rating and an $82 per share target on Teladoc (TDOC), argues that EBITDA guidance for both Q1 and full years 2022 lagged expectations.“While we appreciate that the shares and expectations have come down in recent months, we believe there could be modest pressure as investors digest lower-than-expected profitability and implied ramp throughout,” Santangelo wrote.Despite an Outperform rating, Oppenheimer has also lowered the price target on Teladoc (TDOC) to $130 from $160 to imply a premium of ~99% to the last close.Defending the stock, the analyst Michael Wiederhorn wrote: “We continue to believe that Teladoc is a high risk-high reward name that will need time to play out for investors.”“Overall, while the competitive landscape continues to toughen, we believe the large and growing telehealth pie leaves ample room for multiple competitors to thrive,” he added.Meanwhile, Hims & Hers Health(NYSE:HIMS), another telehealth provider, is continuing to trade higher in the pre-market on Wednesday after its Q4 revenue for2021 more than doubled.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":95,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}